{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:11:30Z","timestamp":1790799090314,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HD086111"],"award-info":[{"award-number":["HD086111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["OD20012"],"award-info":[{"award-number":["OD20012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rett Syndrome Research Trust Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    MECP2 duplication syndrome (MDS) is a rare X-linked neurodevelopmental disorder caused by duplications of the dosage-sensitive methyl-CpG-binding protein 2 (MECP2) gene. Developing therapies for MDS is challenging due to the variability in MECP2 expression among patients and the risk of inducing Rett syndrome through excessive pharmacological intervention. Reducing dosage to optimize silencing often compromises durability and necessitates increased dosing frequency. We present here a series of fully chemically modified small interfering RNAs (siRNAs) designed for isoform-selective and total\n                    <jats:italic>Mecp2<\/jats:italic>\n                    silencing. Among these, we identify six lead siRNA candidates across two chemical scaffolds, achieving targeted total\n                    <jats:italic>Mecp2<\/jats:italic>\n                    expression reductions ranging from 25% to 75%, sustained for at least four months following a single administration. The efficacy and safety of human ortholog silencing are evaluated using a mouse model with ~8-fold human\n                    <jats:italic>Mecp2<\/jats:italic>\n                    transgene expression. In this severe duplication model, a single dose of the total isoform-silencing siRNA rescues early mortality and select behavioral impairments. Overall, this study introduces preclinical candidates for the treatment of MDS. Furthermore, it establishes a target selection strategy applicable to other dosage-sensitive gene imbalances.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75611-7","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:26Z","timestamp":1784624846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Single-dose administration of therapeutic divalent siRNA targeting MECP2 prevents lethality in an MECP2 duplication mouse model"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9624-1244","authenticated-orcid":false,"given":"Vignesh N.","family":"Hariharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5425-0457","authenticated-orcid":false,"given":"Ashley","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Clipperton-Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-2116","authenticated-orcid":false,"given":"Jillian","family":"Caiazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-5623","authenticated-orcid":false,"given":"Daniel","family":"O\u2019 Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8913-0519","authenticated-orcid":false,"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-1624","authenticated-orcid":false,"given":"Zachary","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-0811","authenticated-orcid":false,"given":"Nicholas","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-1707","authenticated-orcid":false,"given":"David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7598-0993","authenticated-orcid":false,"given":"Hassan H.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bogdanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Coenraads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"75611_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1474-4422(20)30217-9","volume":"19","author":"AJ Sandweiss","year":"2020","unstructured":"Sandweiss, A. J., Brandt, V. L. & Zoghbi, H. Y. Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies. Lancet Neurol. 19, 689\u2013698 (2020).","journal-title":"Lancet Neurol."},{"key":"75611_CR2","doi-asserted-by":"publisher","first-page":"1332469","DOI":"10.3389\/fgene.2024.1332469","volume":"15","author":"K Allison","year":"2024","unstructured":"Allison, K., Maletic-Savatic, M. & Pehlivan, D. MECP2-related disorders while gene-based therapies are on the horizon. Front Genet 15, 1332469 (2024).","journal-title":"Front Genet"},{"key":"75611_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/088307380201700105","volume":"17","author":"BB Zeev","year":"2002","unstructured":"Zeev, B. B. et al. Rett syndrome: clinical manifestations in males with MECP2 mutations. J. Child Neurol. 17, 20\u201324 (2002).","journal-title":"J. Child Neurol."},{"key":"75611_CR4","volume":"10","author":"G Chahil","year":"2018","unstructured":"Chahil, G., Yelam, A. & Bollu, P. C. Rett syndrome in males: a case report and review of literature. Cureus 10, e3414 (2018).","journal-title":"Cureus"},{"key":"75611_CR5","doi-asserted-by":"publisher","first-page":"eaaz7785","DOI":"10.1126\/scitranslmed.aaz7785","volume":"13","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome. Sci. Transl. Med. 13, eaaz7785 (2021).","journal-title":"Sci. Transl. Med."},{"key":"75611_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature16159","volume":"528","author":"Y Sztainberg","year":"2015","unstructured":"Sztainberg, Y. et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. Nature 528, 123\u2013126 (2015).","journal-title":"Nature"},{"key":"75611_CR7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s42003-024-06990-0","volume":"7","author":"O Sharifi","year":"2024","unstructured":"Sharifi, O. et al. Sex-specific single-cell-level transcriptomic signatures of Rett syndrome disease progression. Commun. Biol. 7, 1292 (2024).","journal-title":"Commun. Biol."},{"key":"75611_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","volume":"37","author":"JF Alterman","year":"2019","unstructured":"Alterman, J. F. et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat. Biotechnol. 37, 884\u2013894 (2019).","journal-title":"Nat. Biotechnol."},{"key":"75611_CR9","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","volume":"48","author":"CR Brown","year":"2020","unstructured":"Brown, C. R. et al. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates. Nucleic Acids Res. 48, 11827\u201311844 (2020).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/nat.2022.0004","volume":"32","author":"SF Dowdy","year":"2022","unstructured":"Dowdy, S. F., Setten, R. L., Cui, X. S. & Jadhav, S. G. Delivery of RNA therapeutics: the great endosomal escape!. Nucleic Acid Ther. 32, 361\u2013368 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"75611_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","volume":"20","author":"EM Delhaas","year":"2020","unstructured":"Delhaas, E. M. & Huygen, F. Complications associated with intrathecal drug delivery systems. BJA Educ. 20, 51\u201357 (2020).","journal-title":"BJA Educ."},{"key":"75611_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/ner.13325","volume":"24","author":"V Goel","year":"2021","unstructured":"Goel, V. et al. Adverse events and complications associated with intrathecal drug delivery systems: insights from the manufacturer and user facility device experience (MAUDE) database. Neuromodulation 24, 1181\u20131189 (2021).","journal-title":"Neuromodulation"},{"key":"75611_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.604197","volume":"15","author":"V Belov","year":"2021","unstructured":"Belov, V. et al. Large-volume intrathecal administrations: impact on csf pressure and safety implications. Front Neurosci. 15, 604197 (2021).","journal-title":"Front Neurosci."},{"key":"75611_CR14","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/epi.17625","volume":"64","author":"F Fahoum","year":"2023","unstructured":"Fahoum, F. & Eyal, S. Intracerebroventricular administration for delivery of antiseizure therapeutics: challenges and opportunities. Epilepsia 64, 1750\u20131765 (2023).","journal-title":"Epilepsia"},{"key":"75611_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/cge.13521","volume":"95","author":"SU Peters","year":"2019","unstructured":"Peters, S. U. et al. Characterizing the phenotypic effect of Xq28 duplication size in MECP2 duplication syndrome. Clin. Genet. 95, 575\u2013581 (2019).","journal-title":"Clin. Genet."},{"key":"75611_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13072-019-0298-1","volume":"12","author":"A Martinez de Paz","year":"2019","unstructured":"Martinez de Paz, A. et al. MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2. Epigenet. Chromatin 12, 63 (2019).","journal-title":"Epigenet. Chromatin"},{"key":"75611_CR17","doi-asserted-by":"publisher","first-page":"e90645","DOI":"10.1371\/journal.pone.0090645","volume":"9","author":"CO Olson","year":"2014","unstructured":"Olson, C. O., Zachariah, R. M., Ezeonwuka, C. D., Liyanage, V. R. & Rastegar, M. Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements. PLoS One 9, e90645 (2014).","journal-title":"PLoS One"},{"key":"75611_CR18","doi-asserted-by":"publisher","first-page":"13859","DOI":"10.1074\/jbc.M111.309864","volume":"287","author":"M Itoh","year":"2012","unstructured":"Itoh, M. et al. Methyl CpG-binding protein isoform MeCP2_e2 is dispensable for Rett syndrome phenotypes but essential for embryo viability and placenta development. J. Biol. Chem. 287, 13859\u201313867 (2012).","journal-title":"J. Biol. Chem."},{"key":"75611_CR19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1093\/hmg\/ddt640","volume":"23","author":"DH Yasui","year":"2014","unstructured":"Yasui, D. H. et al. Mice with an isoform-ablating Mecp2 exon 1 mutation recapitulate the neurologic deficits of Rett syndrome. Hum. Mol. Genet 23, 2447\u20132458 (2014).","journal-title":"Hum. Mol. Genet"},{"key":"75611_CR20","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1136\/jmg.2004.026161","volume":"42","author":"RE Amir","year":"2005","unstructured":"Amir, R. E. et al. Mutations in exon 1 of MECP2 are a rare cause of Rett syndrome. J. Med. Genet. 42, e15 (2005).","journal-title":"J. Med. Genet."},{"key":"75611_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejmg.2005.11.002","volume":"49","author":"A Quenard","year":"2006","unstructured":"Quenard, A. et al. Deleterious mutations in exon 1 of MECP2 in Rett syndrome. Eur. J. Med. Genet. 49, 313\u2013322 (2006).","journal-title":"Eur. J. Med. Genet."},{"key":"75611_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/ajmg.a.32776","volume":"149A","author":"CJ Saunders","year":"2009","unstructured":"Saunders, C. J., Minassian, B. E., Chow, E. W., Zhao, W. & Vincent, J. B. Novel exon 1 mutations in MECP2 implicate isoform MeCP2_e1 in classical Rett syndrome. Am. J. Med. Genet. A 149A, 1019\u20131023 (2009).","journal-title":"Am. J. Med. Genet. A"},{"key":"75611_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ejhg.2011.145","volume":"20","author":"B Kerr","year":"2012","unstructured":"Kerr, B. et al. Transgenic complementation of MeCP2 deficiency: phenotypic rescue of Mecp2-null mice by isoform-specific transgenes. Eur. J. Hum. Genet 20, 69\u201376 (2012).","journal-title":"Eur. J. Hum. Genet"},{"key":"75611_CR24","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.0610593104","volume":"104","author":"E Giacometti","year":"2007","unstructured":"Giacometti, E., Luikenhuis, S., Beard, C. & Jaenisch, R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc. Natl. Acad. Sci. USA 104, 1931\u20131936 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75611_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1126\/science.1138389","volume":"315","author":"J Guy","year":"2007","unstructured":"Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143\u20131147 (2007).","journal-title":"Science"},{"key":"75611_CR26","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1073\/pnas.0401626101","volume":"101","author":"S Luikenhuis","year":"2004","unstructured":"Luikenhuis, S., Giacometti, E., Beard, C. F. & Jaenisch, R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl. Acad. Sci. USA. 101, 6033\u20136038 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75611_CR27","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/nar\/gkh349","volume":"32","author":"S Kriaucionis","year":"2004","unstructured":"Kriaucionis, S. & Bird, A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res. 32, 1818\u20131823 (2004).","journal-title":"Nucleic Acids Res"},{"key":"75611_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","volume":"23","author":"Q Tang","year":"2024","unstructured":"Tang, Q. & Khvorova, A. RNAi-based drug design: considerations and future directions. Nat. Rev. Drug Discov. 23, 341\u2013364 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"75611_CR29","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/nar\/gky037","volume":"46","author":"MR Hassler","year":"2018","unstructured":"Hassler, M. R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185\u20132196 (2018).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR30","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1093\/nar\/gkaa595","volume":"48","author":"A Biscans","year":"2020","unstructured":"Biscans, A. et al. The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy. Nucleic Acids Res. 48, 7665\u20137680 (2020).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"JK Watts","year":"2012","unstructured":"Watts, J. K. & Corey, D. R. Silencing disease genes in the laboratory and the clinic. J. Pathol. 226, 365\u2013379 (2012).","journal-title":"J. Pathol."},{"key":"75611_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster, D. J. et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol. Ther. 26, 708\u2013717 (2018).","journal-title":"Mol. Ther."},{"key":"75611_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41587-024-02336-7","volume":"43","author":"K Yamada","year":"2024","unstructured":"Yamada, K. et al. Enhancing siRNA efficacy in vivo with extended nucleic acid backbones. Nat. Biotechnol. 43, 904\u2013913 (2024).","journal-title":"Nat. Biotechnol."},{"key":"75611_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.omtn.2022.06.009","volume":"29","author":"SM Davis","year":"2022","unstructured":"Davis, S. M. et al. Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1. Mol. Ther. Nucleic Acids 29, 135\u2013149 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"75611_CR35","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/j.ymthe.2022.04.019","volume":"30","author":"Q Tang","year":"2022","unstructured":"Tang, Q. et al. RNAi-based modulation of IFN-gamma signaling in skin. Mol. Ther. 30, 2709\u20132721 (2022).","journal-title":"Mol. Ther."},{"key":"75611_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42714-4","volume":"14","author":"Q Tang","year":"2023","unstructured":"Tang, Q. et al. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nat. Commun. 14, 7099 (2023).","journal-title":"Nat. Commun."},{"key":"75611_CR37","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1093\/hmg\/ddh282","volume":"13","author":"AL Collins","year":"2004","unstructured":"Collins, A. L. et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet 13, 2679\u20132689 (2004).","journal-title":"Hum. Mol. Genet"},{"key":"75611_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds, A. et al. Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326\u2013330 (2004).","journal-title":"Nat. Biotechnol."},{"key":"75611_CR39","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/nprot.2007.278","volume":"2","author":"A Birmingham","year":"2007","unstructured":"Birmingham, A. et al. A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc. 2, 2068\u20132078 (2007).","journal-title":"Nat. Protoc."},{"key":"75611_CR40","doi-asserted-by":"publisher","first-page":"10905","DOI":"10.1093\/nar\/gky745","volume":"46","author":"T Shmushkovich","year":"2018","unstructured":"Shmushkovich, T. et al. Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs. Nucleic Acids Res. 46, 10905\u201310916 (2018).","journal-title":"Nucleic Acids Res"},{"key":"75611_CR41","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1093\/nar\/gkx818","volume":"45","author":"JK Nair","year":"2017","unstructured":"Nair, J. K. et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 45, 10969\u201310977 (2017).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR42","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/nar\/23.11.2019","volume":"23","author":"LL Cummins","year":"1995","unstructured":"Cummins, L. L. et al. Characterization of fully 2\u2019-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 23, 2019\u20132024 (1995).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR43","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1093\/nar\/gkw1171","volume":"45","author":"E Elkayam","year":"2017","unstructured":"Elkayam, E. et al. siRNA carrying an (E)-vinylphosphonate moiety at the 5\u0384 end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res. 45, 5008 (2017).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1089\/nat.2024.0027","volume":"34","author":"S Allen","year":"2024","unstructured":"Allen, S. et al. mRNA nuclear clustering leads to a difference in mutant huntingtin mrna and protein silencing by siRNAs in vivo. Nucleic Acid Ther. 34, 164\u2013172 (2024).","journal-title":"Nucleic Acid Ther."},{"key":"75611_CR45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1101\/gad.345397.120","volume":"35","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Identification and characterization of conserved noncoding cis-regulatory elements that impact Mecp2 expression and neurological functions. Genes Dev. 35, 489\u2013494 (2021).","journal-title":"Genes Dev."},{"key":"75611_CR46","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/alz.13703","volume":"20","author":"CM Ferguson","year":"2024","unstructured":"Ferguson, C. M. et al. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer\u2019s disease. Alzheimers Dement 20, 2632\u20132652 (2024).","journal-title":"Alzheimers Dement"},{"key":"75611_CR47","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1093\/nar\/gkae368","volume":"52","author":"J Belgrad","year":"2024","unstructured":"Belgrad, J. et al. A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system. Nucleic Acids Res. 52, 6099\u20136113 (2024).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR48","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1016\/j.ymthe.2025.05.010","volume":"33","author":"A Weiss","year":"2025","unstructured":"Weiss, A. et al. RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice. Mol. Ther. 33, 3917\u20133938 (2025).","journal-title":"Mol. Ther."},{"key":"75611_CR49","doi-asserted-by":"publisher","first-page":"e1006780","DOI":"10.1371\/journal.pgen.1006780","volume":"13","author":"MA El-Brolosy","year":"2017","unstructured":"El-Brolosy, M. A. & Stainier, D. Y. R. Genetic compensation: a phenomenon in search of mechanisms. PLoS Genet. 13, e1006780 (2017).","journal-title":"PLoS Genet."},{"key":"75611_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fncel.2015.00056","volume":"9","author":"G Kreiner","year":"2015","unstructured":"Kreiner, G. Compensatory mechanisms in genetic models of neurodegeneration: are the mice better than humans? Front. Cell Neurosci. 9, 56 (2015).","journal-title":"Front. Cell Neurosci."},{"key":"75611_CR51","doi-asserted-by":"publisher","first-page":"R202","DOI":"10.1093\/hmg\/ddp366","volume":"18","author":"JH Nadeau","year":"2009","unstructured":"Nadeau, J. H. Transgenerational genetic effects on phenotypic variation and disease risk. Hum. Mol. Genet. 18, R202\u2013R210 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"75611_CR52","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1093\/nar\/gkac539","volume":"50","author":"MK Schlegel","year":"2022","unstructured":"Schlegel, M. K. et al. From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization. Nucleic Acids Res. 50, 6656\u20136670 (2022).","journal-title":"Nucleic Acids Res."},{"key":"75611_CR53","doi-asserted-by":"publisher","unstructured":"Belgrad, J., et al. Blocking somatic repeat expansion and lowering huntingtin via RNA interference synergize to prevent Huntington\u2019s disease pathogenesis in mice. bioRxiv https:\/\/doi.org\/10.1101\/2025.06.24.661398 (2025).","DOI":"10.1101\/2025.06.24.661398"},{"key":"75611_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker, S. J. et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci. Transl. Med. 16, eadi2245 (2024).","journal-title":"Sci. Transl. Med."},{"key":"75611_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jconrel.2015.12.041","volume":"240","author":"L Crawford","year":"2016","unstructured":"Crawford, L., Rosch, J. & Putnam, D. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system. J. Control Release 240, 251\u2013266 (2016).","journal-title":"J. Control Release"},{"key":"75611_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46\u201351 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"75611_CR57","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","volume":"39","author":"T Nagata","year":"2021","unstructured":"Nagata, T. et al. Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nat. Biotechnol. 39, 1529\u20131536 (2021).","journal-title":"Nat. Biotechnol."},{"key":"75611_CR58","doi-asserted-by":"publisher","first-page":"e129240","DOI":"10.1172\/jci.insight.129240","volume":"4","author":"C Mazur","year":"2019","unstructured":"Mazur, C. et al. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging. JCI Insight 4, e129240 (2019).","journal-title":"JCI Insight"},{"key":"75611_CR59","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","volume":"49","author":"P Jafar-Nejad","year":"2021","unstructured":"Jafar-Nejad, P. et al. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Res. 49, 657\u2013673 (2021).","journal-title":"Nucleic Acids Res"},{"key":"75611_CR60","doi-asserted-by":"publisher","first-page":"e152203","DOI":"10.1172\/jci.insight.152203","volume":"6","author":"CM Ferguson","year":"2021","unstructured":"Ferguson, C. M. et al. Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep. JCI Insight 6, e152203 (2021).","journal-title":"JCI Insight"},{"key":"75611_CR61","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238\u2013248 (2017).","journal-title":"Nat. Biotechnol."},{"key":"75611_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1089\/nat.2015.0578","volume":"26","author":"AH Coles","year":"2016","unstructured":"Coles, A. H. et al. A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo. Nucleic Acid Ther. 26, 86\u201392 (2016).","journal-title":"Nucleic Acid Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75611-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75611-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75611-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:02:06Z","timestamp":1787533326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75611-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75611"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75611-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AK and VNH have filed patent applications related to this work. AK discloses ownership of stocks in Advirna and RXi Pharmaceuticals and is a founder of Atalanta Therapeutics and Comanche Biopharma. VNH is an employee of Comanche Biopharma and owns stock options. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8877"}}